LVS vs PCRX · P/E 28, rev $6.74B vs P/E 174, rev $369.8M
Las Vegas Sands Corp (LVS) versus Pacira BioSciences, Inc. (PCRX) — a side-by-side from cached financials, not a winner call.
Las Vegas Sands Corp (LVS) is a resorts & casinos company listed on US.
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported LVS revenue for 2026-06-30 was $6.74B. Net income was $913.0M. Revenue was up 88.0% from 2026-03-31 to 2026-06-30. LVS currently screens at market cap $35.70B and trailing P/E 28.3.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
LVS currently screens at market cap $35.70B and trailing P/E 28.3. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
Not investment advice. Open the LVS and PCRX stock pages for the full models.
Not investment advice.